Briacell Therapeutics Corporation.

BCTX

Financials

10-KFY 202610/28/26 10-QQ3 ended 04/30/2606/09/26 10-QQ2 ended 01/31/2603/10/26 10-QQ1 ended 10/31/2512/11/25 10-KFY 202510/16/25

Disclosures

8-KRegulation FD Disclosure06/26/26 8-KEntry into Material Agreement; Unregistered Sales of Equity; Other Events06/03/26 8-KRegulation FD Disclosure03/31/26 8-KShareholder Vote Results03/09/26 8-KOther Events02/20/26

Prospectuses and Registrations

424B5Prospectus supplement06/02/26 424B4Prospectus01/14/26 S-1MEFProspectus / registration01/13/26 FWPFree writing prospectus12/23/25 S-1Registration statement (IPO)12/23/25

Proxies

DEF 14ADefinitive proxy02/12/26 DEFA14AAdditional proxy materials01/03/25 DEF 14ADefinitive proxy12/17/24 DEF 14ADefinitive proxy01/09/24 DEF 14ADefinitive proxy07/26/23

Ownership

SC 13GBeneficial ownership01/23/26 SC 13G/ABeneficial ownership (amended)11/07/25 SC 13GBeneficial ownership10/10/25 SC 13GBeneficial ownership07/28/25 SC 13GBeneficial ownership07/22/25

Other

25-NSERemoval from listing02/26/26 8-A12B8-A12B01/13/26 CERTCEO/CFO certification01/13/26 EFFECTRequest for effectiveness01/13/26 CORRESPCorrespondence with the SEC01/08/26